Short answer
NovoCure Ltd (NVCR) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $193M (up 15.7% year over year) with net income of −$10M.
Q3 2026 key financials · XBRL
- Revenue
- $193M
- +15.7% YoY · +5.3% QoQ
- Net income
- −$10M
- +72.0% YoY · +33.4% QoQ
- Operating margin
- -3.2%
- Gross margin
- 77.0%
- EPS (diluted)
- −$0.09
- +72.7% YoY · +30.8% QoQ
Source: XBRL data from the NovoCure Ltd (NVCR) Q3 2026 10-Q on SEC EDGAR. USD.
NovoCure Ltd Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $193.4M, up 16% YoY from $167.2M, driven by 19% global active-patient growth
- Gross margin 77% vs 73% YoY, with Optune Lua revenue $8.2M and Optune Pax revenue $3.7M
- Optune Pax fastest-growing product, $3.7M revenue vs $0.0M YoY; Optune Gio active patients 4,729
- Cash, equivalents and short-term investments $463.5M, up $15.8M from December 31, 2025
- Nine-month operating cash flow $17.3M vs $(31.0)M; tariff volatility and rising launch expenses remain headwinds
Risk Factors
- No material changes to risk factors disclosed in the 2025 10-K
- Carried-forward risks include regulatory, clinical, commercial, operational, and financial uncertainties
- No new or materially updated risk identified in the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NovoCure Ltd quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.